Dr. André Boulet stands as a seasoned entrepreneur and industry leader, bringing a wealth of expertise in drug development, regulatory affairs, market access, financing, and pharmaceutical and biotech restructuring. As the Senior Vice President of Canada Affairs at the American Botanical Drug Association (ABDA), Dr. Boulet plays a pivotal role in shaping the landscape of botanical drug development in the Canadian context.

One of Dr. Boulet's remarkable achievements lies in his role as the driving force behind the success of Thykamine™, the flagship anti-inflammatory drug developed under the Botanical Drug Regulation. Spearheading both the phase 1 and phase 2 clinical programs for ulcerative colitis, he has demonstrated a profound understanding of the complexities of drug development and regulatory pathways. Since 2005, his adept leadership has resulted in the successful raising of over $50 million in private and public equity funding, a testament to his strategic vision and ability to secure financial backing for innovative pharmaceutical ventures.

Prior to his ventures in botanical drug development, Dr. Boulet served as a managing partner in SIPAR's biotech unit, a private investment firm overseeing $400 million in assets. His role as a partner at BioCapital III LP further solidified his standing in the biotech and pharmaceutical investment landscape, showcasing his ability to navigate the intricacies of the financial side of the industry.

Currently serving as the President of Devonian Health Group, a prominent botanical drug corporation in Canada, Dr. Boulet continues to leave an indelible mark on the industry. His leadership at Devonian Health Group reflects a commitment to advancing botanical drug development and contributing to the evolution of healthcare practices.

Dr. André Boulet's journey is characterized by a relentless pursuit of excellence and a commitment to innovation. His multifaceted contributions, from financial structuring to successful clinical program leadership, position him as a visionary entrepreneur in the dynamic and evolving field of drug development. As a key figure in the ABDA, Dr. Boulet continues to shape the narrative of botanical drug development in Canada and beyond.